Company intelligence / Profile preview

Linepharma

London, Greater London, United Kingdomlinepharma.com ↗

Ownership: Private
Development stage: Other

Overview

Linepharma is a global specialty pharmaceutical company focused on improving access to sexual and reproductive healthcare, particularly medication abortion. Its lead products—co-packaged mifepristone and misoprostol—are approved in over 25 countries, including Canada, Australia, and Japan. The company is recognized for developing the world’s first co-packaged mifepristone/misoprostol product specifically for medication abortion, with commercial operations in key international markets.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

Local distributors and non-governmental organizations in Australia, Canada, UK, Asia, Latin America; regulatory partnerships for product approvals.

Beyond the preview

Go deeper on Linepharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Linepharma.

Explore the full profile